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Abstract Recent findings have demonstrated that the GnRH 
gene is expressed in the mammary gland of pregnant and lactating 
rats but not of virgin rats. Indeed, significant concentrations of 
biologically active GnRH have been found in milk of human, cow, 
sheep and rat. We have, therefore, looked for expression of the 
GnRH receptor in the rat mammary gland. By reverse transcrip- 
tion (RT)-PCR amplification, we have demonstrated the presence 
of GnRH receptor mRNA in mammary gland samples derived 
from virgin, pregnant and lactating rats. The GnRH receptor 
transcript cloned from the mammary gland was sequenced and 
found to have an identical coding region to the one cloned from 
the pituitary gland. In addition, we have found that the mammary 
gland, as the pituitary gland, contains at least two transcripts 
having the same coding region but different 5’ non-coding regions. 
Binding studies, however, could demonstrate only low-affinity 
binding sites. These results, therefore, suggest that the regulation 
of the GnRH receptor occurs posttranscriptionally rather than at 
the level of transcription. 
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1. Introduction 
Gonadotropin-releasing hormone (GnRH) is the primary 
regulator of the reproductive cycle. This neurohormone is syn- 
thesized in hypothalamic neurosecretory cells, released in a 
pulsatile pattern and triggers the secretion of the gonadotropic 
hormones, luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) from the anterior pituitary. However, continu- 
ous stimulation of the pituitary by either GnRH or its long- 
acting agonists results in desensitization of the gonadotropes 
and thereby in reduced gonadotropin secretion and suppression 
of gonadal activity. 
Breast cancer is one of the most common cancers in women. 
GnRH agonists are being tested in the clinic as one of the means 
for the treatment of breast cancer. It is generally believed that 
the main therapeutical effect of the GnRH analogs is due to 
desensitization of the pituitary gland resulting from their con- 
tinuous administration. However, the therapeutical effects of 
GnRH analogs on breast tumor regression in postmenopausal 
women cannot be explained on the basis of suppression of 
gonadal activity, since their serum gonadal steroid levels are 
already reduced [ 1,2]. Indeed, there are several studies describ- 
ing direct effects of GnRH analogs on the growth of mammary 
tumor cells in culture [3-51. 
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Recently [6], we have demonstrated that the GnRH gene is 
expressed in the mammary gland of the rat. The GnRH mRNA 
was present in the mammary gland of pregnant and lactating 
rats but not of virgin rats implying that expression of the GnRH 
gene is activated during pregnancy. These findings have com- 
plemented our initial findings [7,8] which demonstrated the 
existence of considerable concentrations of biologically active 
GnRH in milk of several species such as human, cow, sheep and 
rat. GnRH synthesized by the mammary gland may function 
as a paracrinelautocrine agent within the breast itself. Such an 
effect is dependent, however, on the existence of GnRH recep- 
tors in the mammary gland. 
The cDNA encoding the pituitary GnRH receptor of several 
species has been recently cloned, sequenced and characterized 
[9%14]. These studies made it possible to investigate the GnRH 
receptor gene expression in the mammary gland. Although 
conventional binding studies are unable to detect high-affinity 
binding sites in the rat mammary gland, we have found that at 
least two different transcripts of GnRH receptor mRNA are 
expressed in this tissue. 
2. Materials and methods 
2.1. Animals 
Randomly cycling Wistar-derived female rats (2-3 months old) from 
the departmental colony were used. Rats were housed under controlled 
conditions of temperature and light. Food and water were supplied ad 
libitum. Rats were decapitated, tissues were collected and were either 
used immediately or kept at - 140°C until use. 
2.2. RT-PCR analysis of GnRH receptor transcripts 
Rat pituitaries and mammary glands were homogenized by a poly- 
tron and total RNA was extracted using the guanidinium isothiocya- 
nate-CsCl method [15]. After DNAse treatment, 1Opg of the total RNA 
extracts were reverse-transcribed, using 0.5 pg oligo (dT),, as primer 
together with 200 U of Moloney-murine leukemia virus reverse tran- 
scriptase in a total volume of 50 yl, according to the manufacturer’s 
specifications (USB, USA). 1 ~1 of the cDNA was amplified by PCR 
using specific primers to the previously published rat GnRH receptor 
cDNA sequence [1 11. (Primer A) S-GACTCTTGAAGCCCGTCCT- 
TGGAG-3’ and (Primer B) 5’-CGGAAAGCTGCAGTGGGTCAC- 
AC-3’ corresponding to nucleotides - 28 to - 5 (sense) and 584 to 606 
(antisense), respectively. The predicted fragment size was 634 bp. PCR 
amplification was performed in a total volume of 50 ~1 using Vent 
polymerase. Amplification was carried out for 32 cycles; denaturation 
at 94°C for 1 min, annealing at 62°C for 1 min and extension at 72°C 
for 1 min. lo-@ aliquots of each PCR reaction were analysed by electro- 
phoresis and identified by hybridization with a ‘*P-labeled GnRH re- 
ceptor cDNA probe. In parallel experiments, actin mRNA levels were 
assessed using specific- actin primers [16], S’-GAGACCTTCAA- 
CACCCCAGCC-3’ (sense) and 5’-GGCCATCTCTTGCTCGAAG- 
TC-3’ (antisense). . ’ 
For cloning the GnRH receptor cDNA from the rat mammary gland, 
Primer A was used together with Primer C (S’-ACAAGTGCTTGG- 
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GTAGTCTCCC-3’, 987 to 1008; antisense) [ll]. PCR amplification 
was then carried out for 35 cycles; denaturation at 94°C for 1 min, 
annealing at 64°C for I min, and extension at 72°C for 1.5 min. These 
two primers spanned the entire coding region and yielded a fragment 
of 1036 bp, which was subsequently purified and subcloned into the 
SmaI site of the pBluescript KS. The sequence of the cDNA was 
determined by an automated DNA sequencer (Applied Biosystems, 
model 373A). 
Two pituitary GnRH receptor cDNAs having different 5’ non-coding 
regions were cloned recently [12,13]. To look for different transcripts 
of the GnRH receptor in the mammary gland, we used two sense 
primers that are specific for the 5’ non-coding region of each type of 
the pituitary receptor cDNA. For Type I: [12] (primer D) 5’- 
GCCGGTTTCCAGCCGCAGTTT-3’ (- 170 to - 150; sense) and for 
Type II: [ 131 (primer E) 5’-GGCACGCTCGAACTCTTTGTAGG-3’ 
(- 196 to - 174; sense) together with primer B. PCR amplification was 
then carried out for 32 cycles; denaturation at 94°C for 45 s, annealing 
at 62°C for 45 s and extension at 72°C for 1 min. The predicted 
fragment sizes were 776 bp for Type I and 802 bp for Type II. 
2.3. Southern blot analysis 
The DNAs were electrophoretically transferred from 0.75% agarose 
gel onto Gene Screen Plus membrane (DuPont, USA) according to 
manufacturer’s instructions. After transfer, the membrane was baked 
for 2 h at 80°C and prehybridized for 3 h at 42°C with a solution 
containing 2 x SSC, 1% SDS, 10% dextran sulfate, 50% formamide, 
1 x Denhardt’s and 100 &ml denatured salmon sperm DNA. The 
GnRH receptor cDNA probe was prepared by excision from the plas- 
mid using EcoRI and was purified by electroelution. The cDNA was 
labeled by using a random-primed DNA-labeling kit (Boehringer 
Mannheim, Germany). The ‘*P-radiolabeled cDNA probe was then 
added to the prehybridization solution and the membranes were hy- 
bridized for 18 h at 42°C. The membrane was washed as follows: 
(1) 2 x SSC, 2O”C, 10 min; (2) 2 x SSC, 1% SDS, 42”C, 30 min; 
(3) 0.2 x SSC, 1% SDS, 42”C, 30 min. Each step was repeated twice. 
The membrane was then exposed for autoradiography (lc30 min at 
- 70°C). 
2.4. Binding assays 
The procedures for the preparation of the radioiodinated ligand and 
the binding assay have been published [17]. In brief, pituitary (40 pg/ 
protein) or mammary gland (140 &protein) membranes were incu- 
bated with 50,00~100,000 cpm of [‘251][DTrp6]GnRH in a total volume 
of 0.5 ml (10 mM Tris-HCl containing 0.1% BSA) for 90 min at 4°C. 
The reaction was terminated by adding cold PBS and filtration under 
vacuum through Whatman GF/C filters. Pituitary glands were collected 
from proestrus rats whereas mammary glands were taken from pro- 
estrus, pregnant or lactating rats. 
3. Results 
3.1. GnRH receptor expression in rat mammary gland 
RT-PCR analysis using GnRH receptor-specific primers (A 
and B, see section 2) yielded a fragment of 634 bp in mammary 
gland samples derived from pregnant and lactating rats (Fig. 
lA, lanes 2 and 3). The primers encompassed the first exon- 
intron boundary which is located between nucleotides 522-523 
[ 181. A fragment of identical size was obtained in pituitary gland 
cDNA samples which were used as positive control (Fig. lA, 
lane 4). Control reactions in which reverse transcriptase was 
omitted during the RT step did not yield any PCR product, 
ruling out the possibility of plasmid or genomic DNA contam- 
ination (Fig. 1 A, lane 5). To examine whether the appearance 
of GnRH receptor transcripts coincides with that of GnRH [6], 
we used cDNA samples from virgin, 6 and 18 days pregnant, 
6 and 7 days lactating rats. A fragment of similar size was 
detected in all the samples examined. The amplified fragment 
was identified as GnRH receptor cDNA, by direct sequencing 
of the PCR product, and by hybridization with a GnRH recep- 
tor cDNA probe (Fig. 1B). 
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Fig. 1. GnRH receptor transcripts. Panel A: ethidium bromide staining 
of PCR products resolved on 1% agarose gel. For experimental details, 
see section 2. Lanes: (1) kb ladder; (2) mammary gland from 18-day 
pregnant rats; (3) mammary gland from ‘I-day lactating rats; (4) pitui- 
tary gland from virgin rats; (5) mammary gland control sample. All 
samples except the control, in which the reverse transcriptase was omit- 
ted (lane 5), yielded a fragment of 634 bp as predicted. Panel B: South- 
ern blot analysis of GnRH receptor. PCR products from mammary 
gland and pituitary gland were hybridized to a 32P-labeled rat GnRH 
receptor cDNA probe. Lanes: (1) mammary gland of virgin rats; (2) 
mammary gland of 6-day pregnant rats; (3) mammary gland of 18-day 
pregnant rats; (4) mammary gland of 6-day lactating rats; (5) mammary 
gland of 7-day lactating rats; (6) pituitary gland from virgin rats. The 
inset contains ethidium bromide staining of actin transcripts amplified 
from the same cDNA samples. 
For complete sequence analysis, a fragment of 1036 bp span- 
ning the entire coding region of the GnRH receptor (981 bp) 
was amplified from the mammary gland cDNA of virgin rats 
using primers (A and C). Sequence analysis showed (Fig. 2) that 
the coding region of the receptor cloned from the mammary 
gland, was identical with the one cloned from the pituitary 
gland [ll]. 
3.2. GnRH-binding sites 
The GnRH receptor cloned from the mammary gland and 
the one cloned from the pituitary gland had identical coding 
regions. However, specific high-affinity binding sites could be 
demonstrated in the pituitary gland, but not in the mammary 
gland. Displacement curves (Fig. 3) show that the mammary 
gland contains specific low-affinity binding sites for GnRH. 
3.3. Different GnRH receptor transcripts in the mammary gland 
The abovementioned findings suggested that the receptor 
from the mammary gland is regulated differently from that of 
the pituitary gland. Recently, a GnRH receptor cDNA having 
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a different 5’ non-coding region was cloned from a rat pituitary 
library. We have examined the expression pattern of the two 
types of GnRH receptor cDNA in the mammary gland. Since 
amplification of the coding region could not differentiate be- 
tween the two types of cDNA, we used separate forward prim- 
ers (D or E) specific for the 5’ non-coding region of each type 
and a common antisense primer (B). The PCR products were 
identified as GnRH receptor transcripts both by sequencing 
and by hybridization. Fig. 4 shows the hybridization of the 
RT-PCR products with the GnRH receptor cDNA. Type I [12] 
(Fig. 4A) and Type II [13] (Fig. 4B) transcripts were both ex- 
pressed in the pituitary gland (lane 1) as well as in the mammary 
gland (lanes 2-5) cDNA samples. 
4. Discussion 
In this study, we have used the RT-PCR to amplify the levels 
of endogenous GnRH receptor mRNA that may be present in 
rat mammary gland. We have demonstrated the expression of 
mRNA for GnRH receptor in the breast of virgin, pregnant 
and lactating rat (Fig. lA,B). Samples in which the reverse 
transcriptase was omitted have served as a control for genomic 
DNA contamination (Fig. 1A) and confirmed that the frag- 
ments that were amplified originated from RNA. Unlike the 
transcript for GnRH that was evident in mammary glands of 
pregnant and lactating but not of virgin rats [6], the transcript 
for the GnRH receptor was present in the mammary glands of 
all animal models that were examined including the virgin rat. 
The mRNA for the GnRH receptor has also been detected in 
the breast of human [ 191 but not in that of mouse [20], suggest- 
ing a species-specific regulation for this gene. 
Although GnRH receptor transcript is present in the rat 
mammary gland we could not demonstrate specific high-affin- 
ity binding of GnRH analogs to mammary gland preparations. 
Only low-affinity binding could be demonstrated (Fig. 3). Par- 
allel experiments in which pituitary gland preparations were 
used have demonstrated the expected high-affinity binding 
sites. These findings are in agreement with other reports that 
gactcttgaagcccgtcCttggJgAI\AT -1 
ATGGCTAACMTGCGTCTCTTGAGCAGGAGCAGGACCAAAATCACTGCTCAGCCAT 50
CAACAACAGCATCCCCCTGACACAGGGCAAGCTCCCGACTCTMCCTTAT 100 
CTGGAAAGATCCGAGTGACGGTGACl'TTCTTCCTTTTCCTKTCTCTACT 150 
GCCTTCAATGCCTCTTTCTTGGTAMGCTGCAGAGGTGGACCCAGMGAG 200 
GAAGAAAGGJUWUA GCTCTCMGGATGMGGTGCTTTTAAAGCATTTGA 250 
CCTTAGCCMCCTCCTTGAGACI'CTAATCGTCATGCCGCTGGATGGGATG 300 
TGGAACATCACTG?"ICAGTGGTATGCTGGAGAGTTCCTTTGCAAAGTTCT 350 
CAGCTATCTGMGCTCTXTCTATGTATGCCCCAGCCTTCATGATGGTGG 400 
TGATTAGCCTGGATCGCTCCCTGGCCGTCACTCAGCCCTTAGCTGTCCM 450 
AGCMGAGCMGCl'TGMCGGTCTATGACCAGCCTG 500 
CATTGTCTTTGCGGGACCACAGTTATATATCTTCAGGATGATCTACCTAG 550 
CCGACGGCXTGGGCCAGCAGTTTTCTCGCAATGTGTGACCCACTGCAGC 600 
TlTCCGCMTGGTGGCATGMGCC!lTCTACAACTTTTrCACCTTCAGCTG 650 
CCTGTTCATCATCCCTCTTCTCATCATGCTAATCTGCMTGCCAAAATCA 700 
TCTTCGCCCTCACACGAGTCCTTCATCATCAGGACCCACGCAAACTACAGCTG 750 
AATCAATCCMGMTAATATCCCMGAGCACGGCTGAGMCTCTMAGAT 000 
GACAGTGGCATTTGCCACCTCCTTTGTCATCTGCTGGACTCCCTACTACG 050 
TCCTAGGMTCTGGTACTGGTTTGATCCGGAAATGTTMAGTCA 900 
GAGCCAGTCMTCACTTCTTCTTTCTCTTTGCTTTTCTAAACCCGTGCTT 950 
CGACCCACTTATATATGGGTATTTCTCTTTGTMTTgggagxtacccaa 1000 
gcacttgt 1008 
Fig.2.Nucleotide sequence ofthe ratmammarygland GnRH receptor. 
The primers used for the amplification of the cDNA span the entire 
coding region and are shown in lower case letters. 
o! ,‘; 1 a I I 
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Fig. 3. Displacement of [“‘I][DTrp6]GnRH binding to rat pituitary 
(black squares) or mammary gland (open circles) membranes by the 
unlabeled GnRH analog. Each point represents the mean of triplicate 
determinations of a representative experiment, Pituitary gland of proe- 
strus rats and mammary gland of 8-day lactating rats were used in this 
experiment. Maximal binding to the pituitary gland and the mammary 
gland membrane preparations was 40% and 13%, respectively. 
failed to demonstrate high-affinity binding of GnRH to non- 
carcinogenic mammary tissue [21,22]. It was suggested that this 
discrepancy might be due to activation of some genes as a result 
of carcinogenic transformation. However, our results suggest 
that the regulation of GnRH receptor occurs posttranscription- 
ally rather than at the level of transcription. 
Recently, the extrapituitary GnRH receptor cDNA has been 
cloned from a human breast cancer cell line MCF-7 and from 
rat gonads [19,23]. In both reports, the extrapituitary GnRH 
receptor transcripts were found to have nucleotide sequence 
identical with that of the pituitary gland. Although GnRH 
analogs have been demonstrated to exhibit direct effects on 
growth rate of MCF-7 cells [3,4,24], the affinity and even the 
detection of specific binding sites for GnRH in this cell line is 
still a matter of controversy [21,22,24]. 
Heterogeneity of receptors has been recognized to be an 
efficient way for obtaining different biological responses to a 
single hormone stimulation. Different isoforms of rat TRH 
receptors produced by alternative splicing of the receptor RNA 
[25] have recently been isolated. To examine whether a similar 
event occurs with the GnRH receptor, we amplified the entire 
coding region and analysed its sequence. The results demon- 
strate that the sequence of the GnRH receptor cloned from the 
rat mammary gland is identical with that of the pituitary gland 
(Fig. 2). 
It is also possible that a certain protein-coding sequence is 
linked to different 5’ non-coding sequences, as demonstrated 
for the Mz muscarinic receptor [26]. In such events, the differ- 
ential regulation of transcription is achieved by tissue-specific 
promoters, response elements or by transcription factors. In 
fact, different 5’ non-coding regions of the rat pituitary GnRH 
receptor cDNA have been demonstrated [ 12,131. Therefore, it 
was of interest to investigate whether transcripts with different 
5’ non-coding regions are also present in the mammary gland, 
or that there is some tissue specificity. For this purpose, we 
L.N. Levi et al. IFEBS Letters 379 (1996) 186-190 189 
4- 776 bp 
B 
+802 bp 
Fig. 4. Hybridization of the different transcripts with the GnRH recep- 
tor cDNA. RT-PCR products which were amplified using sense primers 
(D and E) specific to the 5’ non-coding region of each transcript and 
a common antisense primer (B), were hybridized with a 32P-labeled 
pituitary GnRH receptor cDNA probe. Hybridization was carried out 
with the Type I transcript (panel A) and with the Type II transcript 
(panel B). For further details, see section 2. Lanes: (1) pituitary gland; 
(2) mammary gland from virgin rats; (3) mammary gland from 6-day 
pregnant rats; (4) mammary gland from 18-day pregnant rats; (5) mam- 
mary gland from 7-day lactating rats. The sizes of the hybridization 
products were 776 bp for Type I and 802 bp for Type Il. 
have used specific primers for the 5’ non-coding regions of the 
two types of the GnRH receptor transcripts. Amplification of 
pituitary and mammary gland cDNAs with these primers has 
shown that the two types of GnRH receptor transcripts are 
present in both tissues (Fig. 4A,B), thus, excluding the possibil- 
ity of tissue-specific regulation for these two transcripts. Al- 
though the methodology used in these experiments was not 
quantitative, there were no striking differences in the pattern 
of the transcripts in relation to the physiological status of the 
animal. The relative amount of the two transcripts did not 
differ in virgin, pregnant and lactating rats, suggesting that the 
regulation of these two transcripts in the mammary gland is 
similar. In these transcripts, the sequence difference starts at 
-32 and goes upstream whereas all the downstream nucle- 
otides including the 3’ non-coding region are identical. 
Some members of the G protein-coupled receptor family 
have been demonstrated to be encoded by more than one gene. 
The different subtypes of somatostatin receptor, for example, 
have distinct tissue distribution and are encoded by different 
genes [27]. Some other members of this family such as the D, 
dopamine receptor [28] are products of alternative splicing 
which again generates transcripts with differences in the amino 
acid sequence. In the M, muscarinic receptor subtype, similar 
to the GnRH receptor, an identical protein-coding region is 
preceded by different regulatory sequences [26]. However, un- 
like the GnRH receptor, each transcript generated by alterna- 
tive splicing, is present in a different tissue, indicating a tissue- 
specific regulation. The functional importance of two different 
transcripts encoding the same protein in the same tissue is not 
known. A recent study has suggested that the downregulation 
of the GnRH receptor in the czT,-1 gonadotrope cell line, is 
accompanied by a decreased efficiency of GnRH receptor 
mRNA translation, without any change in GnRH receptor 
mRNA levels [29]. 
Differential posttranslational modifications of the GnRH re- 
ceptor in the pituitary gland, in the breast as well as in other 
tissues such as the brain, may alter the conformation of the 
receptor leading to changes in ligand affinity and/or specificity. 
Thus, although GnRH administered directly into the mid-brain 
central grey induced mating behavior [30,31], there are no re- 
ports demonstrating the existence of high-affinity binding sites 
in this brain region. Moreover, sexual behavior can be induced 
not only by GnRH but also by some GnRH fragments [31] or 
analogs [30] that are devoid of any agonistic activity at the 
pituitary level. Similarly, it has been demonstrated [32] that the 
affinity of [D-Trp6]GnRH to human breast cancer membranes 
was at least lo-fold higher than that of buserelin. The difference 
in the affinity of these two GnRH analogs is surprising in view 
of their activity at the anterior pituitary level. It seems, there- 
fore, that the currently available GnRH analogs have been 
designed and selected so as to achieve maximal bioactivity at 
the pituitary gland. GnRH receptors may be present in other 
organs but due to different receptor conformation resulting 
from distinct posttranslational modifications, may exhibit in- 
trinsic binding characteristics. 
A considerable amount of GnRH is synthesized by the breast 
[6]. GnRH produced by the mammary gland may act locally in 
a paracrine and/or an autocrine way. Locally produced 
hormones may reach concentrations that will be sufficient for 
binding and activation of their receptor. It is known, for exam- 
ple, that the affinity of various ligands to the muscarinic cholin- 
ergic receptor is in the ,uM range [33,34]. Therefore, it is possi- 
ble that adequate concentrations of GnRH are present in the 
breast tissue to activate low-affinity binding sites. The finding 
that there were no apparent differences in the expression of the 
GnRH receptor mRNA in the mammary gland of intact, preg- 
nant or lactating rats imply that activation of the breast recep- 
tor is regulated by the availability of GnRH. This hormone is 
produced during lactation but not in the virgin cycling female 
rat. During the last decade, however, analogs of GnRH are 
being widely used for various purposes and indications such as 
for treatment in programs of in vitro fertilization, for endomet- 
riosis, precocious puberty, etc. Since GnRH receptors are pres- 
ent in the breast of these patients, it is possible that they will 
be activated by administration of the exogenous GnRH ana- 
logs. The consequences of such an unexpected stimulation are 
still unknown. 
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